Efficacy and Safety of Aflibercept 8 mg in PULSAR Trial in Neovascular AMD

Opinion
Video

Dr. Marion Munk reviews the Phase 3 clinical trial of high-dose aflibercept (8 mg) in neovascular AMD, emphasizing how this new therapy could alleviate the treatment burden for patients while providing superior outcomes.

Recent Videos
Marion Munk, MD, PhD, presenting slides
Related Content
Outlook Therapeutics completes analysis of 12-week safety and efficacy results of NORSE EIGHT

Outlook Therapeutics completes analysis of 12-week safety and efficacy results of NORSE EIGHT

Martin David Harp
January 19th 2025
Article
EyePoint Pharmaceuticals provides company updates, 2025 milestones for Duravyu

EyePoint Pharmaceuticals provides company updates, 2025 milestones for Duravyu

Jordana Joy
January 16th 2025
Article
InflammX Therapeutics enters into option agreement with Bausch + Lomb

InflammX Therapeutics enters into option agreement with Bausch + Lomb

Sydney M Crago
January 16th 2025
Article
Samsara Vision announces positive intermediate-term visual and safety outcomes of SING IMT 6 months post-surgery

Samsara Vision announces positive intermediate-term visual and safety outcomes of SING IMT 6 months post-surgery

Martin David Harp
January 15th 2025
Article
Formycon partners with Teva, Klinge Biopharma for commercialization of aflibercept biosimilar FYB203 (AHZANTIVE)

Formycon partners with Teva, Klinge Biopharma for commercialization of aflibercept biosimilar FYB203 (AHZANTIVE)

Hattie Hayes
January 14th 2025
Article
A connection between sleep apnea and AMD

A connection between sleep apnea and AMD

Lynda Charters
January 10th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.